PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer Holmes Yearley et al. · Nature · 2014
Cited by 6,581 works. doi:10.1038/nature13954 Open-access PDF
Authors
- Paul C. Tumeh
- Christina L. Harview
- Jennifer Holmes Yearley
- I. Peter Shintaku
- Emma J. M. Taylor
- Lídia Robert
- Bartosz Chmielowski
- Gina Henry
- Voicu Ciobanu
- Alisha N. West
- Christine Kivork
- Elizabeth Seja
- Grace Cherry
- Antonio Gutiérrez
- Tristan Grogan
- Christine Mateus
- Gorana Tomasic
- John A. Glaspy
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab